Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HBB | P68871 | 1/20 | 0.44 |
| ▸ | HEXA | P06865 | 1/20 | 0.42 |
| ▸ | HEXB | P07686 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30714451 | 1.00 | CD44 (0.48) | CD44MAOAMAOBCYP3A4TDP1 | |
| SCHEMBL6932597 | 0.84 | ADORA2A (0.50) | CD44MAOACYP3A4TDP1ALDH1A1 | |
| SCHEMBL30158993 | 0.83 | ALDH1A1 (0.45) | CD44MAOAMAOBCYP3A4TDP1 | |
| SCHEMBL31054315 | 0.81 | HEXA (0.47) | CD44CYP3A4TDP1ALDH1A1L3MBTL1 | |
| SCHEMBL9678804 | 0.77 | CYP3A4 (0.54) | CD44MAOACYP3A4TDP1ALDH1A1 | |
| SCHEMBL29447448 | 0.77 | POLB (0.52) | CD44MAOAMAOBCYP3A4TDP1 | |
| SCHEMBL9296990 | 0.77 | POLB (0.52) | CD44MAOAMAOBCYP3A4TDP1 | |
| SCHEMBL8361077 | 0.76 | CD44 (0.52) | CD44MAOAMAOBCYP3A4TDP1 | |
| SCHEMBL1133067 | 0.76 | MYC (0.56) | CD44CYP3A4TDP1ALDH1A1NPC1 | |
| SCHEMBL3794848 | 0.76 | CD44 (0.62) | CD44CYP3A4TDP1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116107124-A | Dye-enhanced three-color liquid crystal display device | 西京学院 | 2023-05-12 | — | — | CN | claimed |
| CN-117396540-A | Polyimide resin material for colorless transparent processed product, and novel polyimide | 本州化学工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| CN-116107124-A | Dye-enhanced three-color liquid crystal display device | 西京学院 | 2023-05-12 | — | — | CN | disclosed |
| US-20100298559-A1 | OPTICALLY ACTIVE DINICKEL COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE USING THE OPTICALLY ACTIVE DINICKEL COMPLEX AS CATALYST | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-11-25 | — | — | US | disclosed |
| EP-2233468-A1 | OPTICALLY ACTIVE DINICKEL COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE USING THE OPTICALLY ACTIVE DINICKEL COMPLEX AS CATALYST | Nissan Chemical Industries, Ltd. (JP) | 2010-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298559-A1 | OPTICALLY ACTIVE DINICKEL COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE USING THE OPTICALLY ACTIVE DINICKEL COMPLEX AS CATALYST | C5, C9, CCNE1 | CD44 4530/4885MAOA 493/4885MAOB 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.